Publications (5)7.31 Total impact

  • Norma Cameli · Elva Abril · Marina Agozzino · Maria Mariano ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Solar lentigines are common benign macular hyperpigmented lesions localized on sun-exposed areas. To evaluate the efficacy and safety of a new depigmenting agent containing a retinoid (retinaldehyde), a new phenolic agent (4-(1-phenylethyl)-resorcinol) and a reducing agent (δ-tocopheryl-β-D-glucopyranoside) in the topical treatment of solar lentigines. Twenty patients with solar lentigines of the face and hands applied the depigmenting agent on each lentigo once daily for 12 weeks. The outcome was evaluated at 45 days (T1) and 3 months (T2) after the end of treatment compared to baseline (T0) by means of clinical evaluation, Mexameter® and Visioface devices for digital and ultraviolet computerized image analysis of skin color as well as in vivo reflectance confocal microscopy. Image analysis and confocal laser reflectance microscopy showed that hyperpigmentation was significantly reduced at T2 compared to baseline and to controls. The study treatment was well tolerated and showed significant improvement in the depigmentation of solar lentigines. © 2015 S. Karger AG, Basel.
    Dermatology 04/2015; 230(4). DOI:10.1159/000379746 · 1.57 Impact Factor
  • Norma Cameli · Elva Abril · Maria Mariano · Enzo Berardesca ·
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND Melasma is a common acquired pigmentary disorder that has a considerable psychological impact on the patient. The recurrent and refractory nature of this condition makes it difficult for treatment. OBJECTIVE We aim to evaluate the efficacy and safety of a combined system that simultaneously uses monopolar radiofrequency (RF) and transdermal drug delivery of phytocomplex containing 1% kojic acid in the treatment of melasma. MATERIALS AND METHODS Fifty patients affected by melasma underwent 6 sessions of treatment at 1-week intervals. The outcome was evaluated before treatment (T-0) and 1 month (T-1) and 6 months (T-2) after treatment using the Melasma Area and Severity Index score, a Mexameter, and Visioface devices for digital and ultraviolet computerized image analysis of skin color.RESULTSThe image analysis showed that hyperpigmentation was significantly reduced at T-1 and T-2 compared with baseline. Melasma Area and Severity Index score, the average melanin score, and the average erythema values showed a significant reduction. No side effects were observed or reported. CONCLUSION This study describes the first report of improvement in melasma through the combined use of monopolar RF with transdermal delivery of depigmenting agents. This could be a safe, tolerable, and effective alternative tool for the treatment of melasma.
    Dermatologic Surgery 07/2014; 40(7):748-755. DOI:10.1111/dsu.0000000000000029 · 2.11 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT:   Rosacea is a chronic inflammatory skin disease affecting mostly facial skin. Its origin is multifactorial. Important steps in its treatment are avoidance of any triggering factor and control of skin inflammation.   To assess the benefit of topical applications of a new product (P-3075).   A randomized, multicenter, double-blind, placebo-controlled, parallel-group, pilot study was carried out to evaluate the efficacy and tolerability of a cream (P-3075) based on 5% potassium azeloyl diglycinate (PAD, Azeloglicina(®)) and 1% hydroxypropyl chitosan (HPCH). Forty-two patients (rosacea stages I and II) were enrolled and randomized, 28 in the P-3075 group and 14 in the placebo group. They were asked to apply the cream twice daily for 4 weeks. The main assessments were the objective quantification of erythema and skin hydration using the Mexameter(®) and Corneometer(®) devices, respectively. Clinical signs and symptoms were evaluated on a four-point scale.   The P-3075 cream applied for 28 days was effective in skin protection by reducing erythema, evaluated both instrumentally and clinically. In addition, the clinical assessments of other symptoms such as flushing, stinging, and burning supported the beneficial effect of the P-3075 cream.   The anti-inflammatory and moisturizing effects of potassium azeloyl diglycinate combined with the protective properties of HPCH allow the new product to be a good candidate for controlling signs and symptoms of rosacea.
    Journal of Cosmetic Dermatology 03/2012; 11(1):37-41. DOI:10.1111/j.1473-2165.2011.00598.x · 0.88 Impact Factor
  • E Berardesca · E Abril · C Rona · R Vesnaver · A Cenni · M Oliva ·
    [Show abstract] [Hide abstract]
    ABSTRACT: So-called 'sex-specific fat' appears to be physiologically advantageous, but it has a cosmetic downside as well. A pool of functional ingredients, principally represented by botanical extracts, was selected to treat this condition, specifically for people intimidated by other more invasive approaches. The topical product was formulated using ingredients aimed at two specific actions; adipolysis and microcirculation stimulation [1-4]. The product was conceived for night-time application because during the night the body releases Growth Hormone, which activates adipolysis and blood flow, and the skin barrier function and metabolic rate are also more active. We aimed at assessing the effect of the topical product vs. placebo through an in vivo evaluation protocol, performed using a skin bioengineering method, namely ultrasonography, and clinical evaluation. The protocol was conducted as a double-blind, active vs. placebo trial (form. N°690 vs. form. N°1362), on 100 subjects enrolled by two research centres (Pavia and Rome, Italy), over a 4 week period, during which volunteers were checked four times, both clinically and instrumentally. At the end of the trial, both centres agreed on the slimming effects of the topical product. Tolerability was good. The enrolled volunteers expressed their full satisfaction regarding the product under study.
    International journal of cosmetic science 02/2012; 34(3):263-72. DOI:10.1111/j.1468-2494.2012.00712.x · 1.38 Impact Factor
  • E Berardesca · E Abril · M Serio · N Cameli ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Sensitive skin is a dermatological problem of increasing incidence in western countries and is sometimes associated with atopic condition and bacterial sovrainfection. The purpose of this study is to evaluate in a double blind, randomized, placebo controlled trial the efficacy of gluco-oligosaccharide and collagen tripeptide F in controlling the signs and symptoms of sensitive atopic skin. Forty female subjects (age, 30-59 years) affected by non-lesional atopic sensitive skin entered the study. Skin sensitivity was determined by a dermatologist on the basis of medical history, stinging test, dermatological examination and a questionnaire. A treatment with the test products (active and placebo) was carried out for 4 weeks. Measurements and clinical evaluation were carried out at baseline and at the end of the study. The following objective parameters investigated were bacterial count, skin pH and colour, transepidermal water loss (TEWL), stratum corneum hydration, skin roughness and mechanical properties. Clinical assessment included also a scoring system for dryness, desquamation, irritation, erythema and papules. Significant differences were found in the active treated group when compared with the placebo and in particular for instrumental parameters of roughness (P < 0.02), volume (P < 0.01), TEWL (P < 0.02), erythema (P < 0.0006) and clinical parameters of dryness, desquamation and irritation (P < 0.001). Moisturization levels and skin colour improved significantly in both the active and placebo groups. In conclusion, the study shows that the modulation of bacterial proliferation and normalization of skin barrier properties and stratum corneum moisturization can improve the symptoms of sensitive skin.
    International journal of cosmetic science 07/2009; 31(4):271-7. DOI:10.1111/j.1468-2494.2009.00495.x · 1.38 Impact Factor

We use cookies to give you the best possible experience on ResearchGate. Read our cookies policy to learn more.